Investigation of the Long-Term Effects of Amantadine Use in Parkinson's Disease.
作者信息
Park Sangmin, Shin Jung Hwan, Jeon Seung Ho, Lee Chan Young, Kim Han-Joon, Jeon Beomseok
机构信息
Department of Neurology, Eulji University Hospital, Eulji University School of Medicine, Daejeon, Korea.
Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
出版信息
J Mov Disord. 2023 May;16(2):224-226. doi: 10.14802/jmd.23037. Epub 2023 May 24.
Abstract
摘要
相似文献
1
Investigation of the Long-Term Effects of Amantadine Use in Parkinson's Disease.金刚烷胺用于帕金森病的长期效果研究。
J Mov Disord. 2023 May;16(2):224-226. doi: 10.14802/jmd.23037. Epub 2023 May 24.
2
Aminoadamantanes: from treatment of Parkinson's and Alzheimer's disease to symptom amelioration of long COVID-19 syndrome?金刚烷胺类药物：从治疗帕金森病和阿尔茨海默病到改善长新冠综合征的症状？
Expert Rev Clin Pharmacol. 2023 Feb;16(2):101-107. doi: 10.1080/17512433.2023.2176301. Epub 2023 Feb 8.
3
GOCOVRI (amantadine) extended-release capsules in Parkinson's disease.用于帕金森病的 GOCOVRI（金刚烷胺）缓释胶囊。
Neurodegener Dis Manag. 2022 Feb;12(1):15-28. doi: 10.2217/nmt-2021-0028. Epub 2021 Dec 17.
4
Amantadine in Parkinson's disease: pro and contra.金刚烷胺在帕金森病中的应用：利弊
J Neural Transm Suppl. 1995;46:415-21.
5
Amantadine Revisited: A Contender for Initial Treatment in Parkinson's Disease?金刚烷胺再探讨：帕金森病初始治疗的候选药物？
CNS Drugs. 2021 Nov;35(11):1141-1152. doi: 10.1007/s40263-021-00862-5. Epub 2021 Oct 14.
6
Amantadine in Parkinson's disease. A double-blind, placebo-controlled, crossover study with long-term follow-up.金刚烷胺治疗帕金森病。一项双盲、安慰剂对照、交叉试验及长期随访研究。
Neurology. 1975 Jul;25(7):603-6. doi: 10.1212/wnl.25.7.603.
7
The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients.缓释金刚烷胺在帕金森病患者运动障碍治疗中的作用。
Neurodegener Dis Manag. 2018 Apr;8(2):73-80. doi: 10.2217/nmt-2018-0001. Epub 2018 Mar 22.
8
Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial.金刚烷胺治疗帕金森病运动障碍的随机对照试验。
PLoS One. 2010 Dec 31;5(12):e15298. doi: 10.1371/journal.pone.0015298.
9
Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa.运动障碍中尿中单胺代谢产物的排泄。金刚烷胺和左旋多巴的作用。
J Neurol Sci. 1977 Jun;32(2):219-25. doi: 10.1016/0022-510x(77)90237-4.
10
Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.金刚烷胺对重度帕金森病运动障碍的疗效持续时间。
J Neurol Neurosurg Psychiatry. 2004 Jan;75(1):141-3.
本文引用的文献
1
Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.帕金森病非运动症状治疗的研究进展——基于循证医学的评价
Mov Disord. 2019 Feb;34(2):180-198. doi: 10.1002/mds.27602. Epub 2019 Jan 17.
2
Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson's Disease: An Open-Label, Pragmatic Trial.金刚烷胺与早期帕金森病患者运动障碍风险：一项开放标签的实用性试验。
J Mov Disord. 2018 May;11(2):65-71. doi: 10.14802/jmd.18005. Epub 2018 May 30.
3
International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.国际帕金森病和运动障碍学会循证医学综述：帕金森病运动症状治疗的最新进展。
Mov Disord. 2018 Aug;33(8):1248-1266. doi: 10.1002/mds.27372. Epub 2018 Mar 23.
4
Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.帕金森病运动障碍患者中停用金刚烷胺：AMANDYSK 试验。
Neurology. 2014 Jan 28;82(4):300-7. doi: 10.1212/WNL.0000000000000050. Epub 2013 Dec 26.
5
Long-term antidyskinetic efficacy of amantadine in Parkinson's disease.金刚烷胺治疗帕金森病的长期抗运动障碍疗效。
Mov Disord. 2010 Jul 30;25(10):1357-63. doi: 10.1002/mds.23034.
6
Amantadine for fatigue in multiple sclerosis.金刚烷胺治疗多发性硬化症疲劳
Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD002818. doi: 10.1002/14651858.CD002818.pub2.
7
Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.金刚烷胺对重度帕金森病运动障碍的疗效持续时间。
J Neurol Neurosurg Psychiatry. 2004 Jan;75(1):141-3.
Zotero 插件